<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
	<meta http-equiv="X-UA-Compatible" content="IE=edge" />
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
	<meta name="viewport" content="width=300, initial-scale=1.0, minimum-scale=1.0,maximum-scale=1.0"/>
	<link rel="stylesheet" href="css/styles.css" type="text/css">
	<link rel="stylesheet" href="css/intubation.css" charset="utf-8">
	<title>Mivacron | Intubation</title>
	<script type="text/javascript">
			function overlay() {
				el = document.getElementById("overlay");
				el.style.visibility = (el.style.visibility == "visible") ? "hidden" : "visible";
			}

			function overlay2() {
				el = document.getElementById("overlay2");
				el.style.visibility = (el.style.visibility == "visible") ? "hidden" : "visible";
			}

			function overlay5() {
				el = document.getElementById("overlay5");
				el.style.visibility = (el.style.visibility == "visible") ? "hidden" : "visible";
			}
	</script>
</head>
<body>
	<div class="main-wrap">
		<div class="left-column-2">
			<div class="mivacron-video-1">
				<video src="videos/Intubation_main.mp4" autoplay="autoplay" type="video/mp4">
			</div>
			<div class="blue-text">
				<p class="larger-header">
					<strong>MIVACRON®</strong> (mivacurium chloride) <strong>injection PROVIDES GOOD-to-EXCELLENT INTUBATING CONDITIONS<br><span class="smaller-header">WITHIN 1.5–3 MINUTES, DEPENDING ON THE DOSE<sup>1*,†</sup></span></strong>
				</p>
			</div>
			<div class="purple-bar-text">
				<img class="purple-bar-text-img" src="images/purple-bar.png" />
				<p>
					<strong>Time to generally good-to-excellent intubating conditions<sup>1</sup></strong>
				</p>
				<img class="leg-graph" src="images/intubation-graph-leg.png" />
			</div>
			<div class="intubation-graph-wrap">
				<img class="intubation-graph" src="images/intubation-graph.png" />
				<img class="graph-overlay" src="videos/animations/intubation.gif" />
			</div>
			<div class="graph-notes">
				<p><sup>*</sup>Dosing range studied: 0.15 mg/kg (2.5–3 mins) to 0.25 mg/kg (1.5–2 mins)<br></p>
					<p><sup>†</sup>After completion of 0.15 mg/kg to 0.25 mg/kg dose</p>
			</div>
			<div class="footer-btn">
				<strong><p>Please see accompanying full<br>Prescribing Information.</p></strong>
				<a href="#" onclick="overlay()"><img class="btn-1" src="images/isi-btn.png" /></a>
				<a href="#" onclick="overlay2()"><img class="btn-2" src="images/isi-btn-2.png" /></a>
				<a href="#" onclick="overlay5()"><img class="btn-3" src="images/char-notes-btn.png" /></a>
			</div>
			</div>
			<div class="right-column">
				<p><strong>SAFETY CONSIDERATIONS</strong></p>
				<div class="right-col-text">
					</ul>
						<li><strong>MIVACRON should only &nbsp;&nbsp;be administered &nbsp;&nbsp;intravenously in carefully &nbsp;&nbsp;adjusted dosage by or &nbsp;&nbsp;under the supervision of &nbsp;&nbsp;experienced clinicians &nbsp;&nbsp;who are familiar with the &nbsp;&nbsp;drug’s actions and the &nbsp;&nbsp;possible complications.</strong></li>
						<br>
						<li><strong>It is recommended that a &nbsp;&nbsp;peripheral nerve &nbsp;&nbsp;stimulator be used during &nbsp;&nbsp;the administration of &nbsp;&nbsp;MIVACRON to monitor &nbsp;&nbsp;drug effect, determine the &nbsp;&nbsp;need for additional drug, &nbsp;&nbsp;and confirm &nbsp;&nbsp;recovery &nbsp;&nbsp;from neuromuscular block.</strong></li>
						<br>
						<li><strong>MIVACRON has no &nbsp;&nbsp;known effect on &nbsp;&nbsp;consciousness, pain &nbsp;&nbsp;threshold, or cerebration.</strong></li>
					</ul>
				</div>
			</div>
			<div class="logo">
				<img class="short-act-logo" src="images/logo.png" />
			</div>
		</div>
		<div id="overlay" a href"#" onclick='overlay()'></a>
			<div class="modal">
				<div class="inner-safety-wrap">
					<a href="JavaScript:window.close()"><img class="exit-btn" src="images/x.png" /></a>
					<h2>INDICATION<sup>1</sup></h2>
					<p>
						MIVACRON® (mivacurium injection chloride) is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia,
						to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
					</p>
					<h2>IMPORTANT SAFETY INFORMATION<sup>1</sup></h2>
					<p>
						<ul>
							<li>MIVACRON is contraindicated in patients with known hypersensitivity to the product and its components.</li>
							<li>Severe anaphylactic reactions to neuromuscular blocking agents, including MIVACRON, have been reported. These reactions have in some cases been life-threatening and fatal. Necessary precautions, including the immediate availability of appropriate emergency treatment, should be taken. Precautions should also be taken in individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents.</li>
							<strong><li>MIVACRON should only be administered intravenously in carefully adjusted dosage by or under the supervision of experienced clinicians who are familiar with the drug’s actions and the possible complications.
							<li>It is recommended that a peripheral nerve stimulator be used during the administration of MIVACRON to monitor drug effect, determine the need for additional drug, and confirm recovery from neuromuscular block.
							<li>MIVACRON has no known effect on consciousness, pain threshold, or cerebration.
							<li>MIVACRON is metabolized by plasma cholinesterase and should be used with great caution, if at all, in patients suspected of being homozygous for the atypical plasma cholinesterase gene due to the possibility of prolonged neuromuscular block.</strong> Plasma cholinesterase activity may be diminished in patients with genetic abnormalities of plasma cholinesterase, pregnancy, liver or kidney disease, malignant tumors, infections, burns, anemia, decompensated heart disease, peptic ulcer, or myxedema. The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase.
							<li>Exercise caution when administering MIVACRON to patients with clinically significant cardiovascular disease, obesity, or any history suggesting sensitivity to the release of histamine (e.g., asthma), as a transient decrease in mean arterial pressure related to histamine release is possible.
							<li>MIVACRON will not counteract the bradycardia produced by many anesthetic agents or by vagal stimulation.
							<img class="isi-arrow-2" src="images/ISI-arrow.png" />
							<li>Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC decreases the ED50 of MIVACRON. Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, quinidine, and succinylcholine.
							<li>Adverse events: >1% of the surgical patients treated with MIVACRON during clinical trials reported flushing (16%); < 1% of patients reported hypotension, tachycardia, bradycardia, cardiac arrhythmia, phlebitis, bronchospasm, wheezing, hypoxemia, rash, urticaria, erythema, injection site reaction, prolonged drug effect, dizziness, or muscle spasms.
						</ul>
					</p>
				</div>
			</div>
		</div>
		<div id="overlay2" a href="#" onclick='overlay2()'></a>
			<div class="modal-2">
				<div class="inner-safety-wrap">
					<a href="JavaScript:window.close()"><img class="exit-btn" src="images/x.png" alt="" /></a>
					<p><strong>References:</strong></p>
					<ul>
						<li><strong>1.</strong> MIVACRON [package insert]. North Chicago, IL: AbbVie Inc.
						<li><strong>2.</strong> Savarese JJ, Ali HH, Basta SJ, et al. The clinical neuromuscular pharmacology of mivacurium chloride<br>&nbsp;&nbsp;&nbsp;(BW B1090U).
						 A short-acting nondepolarizing ester neuromuscular blocking drug. <i>Anesthesiology.</i> &nbsp;&nbsp;&nbsp;1988;68(5):723-732.
						<li><strong>3.</strong> Apfelbaum JL. Mivacurium chloride administration by infusion. <i>Acta Anaesthesol Scand.</i> 1995;39<br>&nbsp;&nbsp;&nbsp;(suppl s106):55-57.
						<li><strong>4.</strong> NIMBEX [package insert]. North Chicago, IL: AbbVie Inc.
						<li><strong>5.</strong> Rocuronium Bromide Injection [package insert]. Parsippany, NJ: The Medicines Company; 2012.
						<li><strong>6.</strong> Vecuronium Bromide for Injection [package insert]. Schaumburg, IL; Sagent Pharmaceuticals, Inc; 2011.
						<li><strong>7.</strong> Pancuronium Bromide Injection [package insert]. Lake Forest, IL: Hospira, Inc; 2014.
						<li><strong>8.</strong> Atracurium Besylate Injection [package insert]. Deerfield, IL: Baxter Healthcare Corporation; 2006.
						<li><strong>9.</strong> Tang J, Joshi GP, White PF. Comparison of rocuronium and mivacurium to succinylcholine during outpatient
						&nbsp;&nbsp;&nbsp;&nbsp;laparoscopic surgery. <i>Anesth. Analg.</i> 1996;82:994-998.
					</ul>
				</div>
			</div>
		</div>
		<div id="overlay5" a href="#" onclick='overlay5()'></a>
			<div class="modal-5">
				<div class="inner-safety-wrap">
					<a href="JavaScript:window.close()"><img class="exit-btn" src="images/x.png" alt="" /></a>
					<p>CHART NOTE: When administered during the induction of
						adequate general anesthesia using thiopental or propofol, nitrous oxide/oxygen, and coinduction agents such as fentanyl and/or midazolam, doses of 0.15 mg/kg (2 x ED95) MIVACRON
						administered over 5–15 seconds or 0.2 mg/kg MIVACRON
						administered over 30 seconds produced generally
						good-to-excellent tracheal intubation conditions in 2.5–3 and 2–2.5 minutes, respectively. A dose of 0.25 mg/kg MIVACRON administered as a divided dose (0.15 mg/kg followed
						30 seconds later by 0.1 mg/kg) produced generally
						good-to-excellent intubation conditions in 1.5–2 minutes after initiating the dosing regimen.<sup>1</sup></p>
					</ul>
				</div>
			</div>
		</div>
</body>
</html>
